Active	Status	Sponsor type	Region	Phase	Filter
8 Active 0 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Riaz, Muhammad
DREAM3R, NCT04334759: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma	Active, not recruiting	3	214	US, RoW	Durvalumab, MEDI4736, Imfinzi, Standard Chemotherapy, Cisplatin or Carboplatin and Pemetrexed, Ipilimumab and Nivolumab, Yervoy, Opdivo	PrECOG, LLC., AstraZeneca, Thoracic Oncology Group Australasia (TOGA), University of Sydney	Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma	06/25	02/26
OpcemISA, NCT03669718 / 2018-000789-13: A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC	Active, not recruiting	2	194	Europe, US, RoW	ISA101b, Cemiplimab, Placebo	ISA Pharmaceuticals, Regeneron Pharmaceuticals	Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive	09/24	06/25
NCT03808558: Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas	Active, not recruiting	2	18	US	TVB-2640	David E Gerber, Sagimet Biosciences Inc., Cancer Prevention Research Institute of Texas, Gateway for Cancer Research	KRAS Gene Mutation	04/25	12/26
KEYSTROKE, NCT03546582: SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma	Recruiting	2	102	Canada, US	Pembrolizumab, Keytruda, Stereotactic Body Radiation Therapy (SBRT), SBRT	RTOG Foundation, Inc., Merck Sharp & Dohme LLC	Head and Neck Squamous Cell Carcinoma (HNSCC)	07/27	07/29
NCT03440437: A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies Apr 2022 - Sep 2022 : From trial for advanced cancer For advanced cancer Nov 2020 - Nov 2020: For advanced cancer	Terminated	1/2	80	Europe, US	FS118, Paclitaxel	invoX Pharma Limited	Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck	06/24	06/24
Monroe, Ilaina
KEYSTROKE, NCT03546582: SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma	Recruiting	2	102	Canada, US	Pembrolizumab, Keytruda, Stereotactic Body Radiation Therapy (SBRT), SBRT	RTOG Foundation, Inc., Merck Sharp & Dohme LLC	Head and Neck Squamous Cell Carcinoma (HNSCC)	07/27	07/29